Butovent (Salbutamol) is generally used to help patients manage symptoms related to reversible obstructive airway disease. The medication generally provides supportive symptomatic relief in conditions such as Bronchial Asthma and Chronic Obstructive Pulmonary Disease (COPD).

Key Therapeutic Focus

The medication's role is commonly aligned with providing acute symptomatic relief when symptoms appear suddenly or intensify. It is relevant for easing challenging symptoms that create noticeable physiological strain, which includes manifestations of bronchospasm. This includes addressing groups of symptoms like wheezing, chest tightness, and shortness of breath associated with conditions such as asthma, chronic bronchitis, and emphysema.

Butovent is commonly used during phases when symptoms become more noticeable, offering symptomatic relief that helps patients cope more steadily with difficult episodes. It is also applied in prevention scenarios, such as before exercise-induced bronchoconstriction (EIB), to help maintain a sense of stability during activity.

Quick Fact: Relief for Acute Breathing Distress

Regulatory References

1. NIH MedlinePlus overview

Eligibility Map: Who Can and Cannot Use Butovent — Official Regulatory Information

The eligibility profile for Butovent (Salbutamol/Albuterol) is defined by mandatory constraints and cautions documented in government regulatory sources, strictly outlining who may be considered for treatment.

Populations for whom use is contraindicated: Butovent must not be used in patients with a known history of hypersensitivity to the active substance (Salbutamol/Albuterol) or any other components of the specific formulation. Non-intravenous forms are also contraindicated for the management of threatened abortion or uncomplicated premature labour.

Age-related eligibility rules: Butovent is generally indicated for use in adults and children aged 4 years and older for most inhaled forms. Safety and effectiveness have not been established for most inhaled formulations in children under 4 years of age.

Condition-specific eligibility rules: The medicine should be administered with caution to patients with certain underlying conditions due to its sympathomimetic effects. These include cardiovascular disorders (such as coronary insufficiency, cardiac arrhythmias, and hypertension), thyrotoxicosis (overactive thyroid), and diabetes mellitus. Patients with or at risk of hypokalaemia (low potassium levels) also require close monitoring.

Pregnancy and lactation eligibility status: Use during pregnancy is conditional; administration is only considered if the expected benefit to the mother is greater than any possible risk to the foetus. Use is generally not recommended in nursing mothers as the drug may be secreted in breast milk.

Interactions with other medicines and products

The official prescribing information for Butovent (Salbutamol) documents specific interaction patterns with other medicinal products, primarily structured around pharmacodynamic effects and one noted pharmacokinetic outcome.

Prohibited and Restricted Combinations

The co-administration of Butovent with non-selective beta-adrenergic blocking drugs (such as propranolol) is formally restricted or generally avoided in patients with reversible obstructive airway disease. This constraint is due to the documented risk of inhibiting the bronchodilator action, which can lead to the clinical event of severe bronchospasm.

Pharmacodynamic and Metabolic Interactions

The concurrent use of Butovent with certain agents is associated with a formal risk of hypokalemia (low serum potassium levels) described in regulatory labels. These interacting agents include Diuretics (non-potassium-sparing), Xanthine derivatives, and Corticosteroids. Additionally, regulatory documents note that both Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs) may potentiate the effect of Salbutamol on the vascular system. This potential for increased blood glucose levels with corticosteroids is also specifically noted as being exaggerated in diabetic patients.

Exposure and Procedural Constraints

The regulatory profile notes a potential alteration of serum exposure with Digoxin, where co-administration may result in a decrease in Digoxin concentrations. A procedural constraint exists when administering nebulized Salbutamol with Anticholinergics: patients must be warned to prevent the solution or mist from making contact with the eye, due to the reported risk of angle-closure glaucoma associated with this combination.

Butovent is a selective beta2-adrenergic agonist that binds to beta2-receptors primarily located on bronchial smooth muscle cells. The binding interaction facilitates a conformational change in the receptor. This receptor activation leads to the stimulation of adenylyl cyclase, an enzyme that catalyzes the conversion of ATP into cyclic adenosine monophosphate (cAMP), increasing its intracellular concentration. The elevated cAMP then acts as a second messenger, activating Protein Kinase A (PKA). PKA mediates a reduction in intracellular calcium concentrations by affecting calcium-regulating proteins. This reduction in calcium results directly in the relaxation of bronchial smooth muscle fibers. Furthermore, the mechanism also includes the inhibition of bronchoconstricting mediators released from mast cells and other inflammatory cells in the airway, which restricts the subsequent release of additional inflammatory cellular products.

How Butovent is Used in Clinical Practice

The usage of Butovent (Salbutamol or Albuterol) is defined by clinical guidelines outlining the delivery methods, fixed dose ranges, and timing protocols. The primary purpose of this medication, consistent with its classification as a Short-Acting beta2-Agonist (SABA), is its intermittent, as-needed use for acute symptomatic episodes.

Official Administration Routes and Forms

Butovent is most commonly delivered via oral inhalation using a pressurized Metered-Dose Inhaler (pMDI) or an inhalation solution administered through a nebulizer device. For severe acute conditions, parenteral administration via Intravenous (IV), Subcutaneous (SC), or Intramuscular (IM) injection is an approved route, typically reserved for hospital settings.

Standard Dosing and Frequency

For the pMDI, the standard dose for acute relief is generally 1 to 2 inhalations (100 mcg to 200 mcg total) taken as required. When used to prevent exercise-induced symptoms, the dose is typically 2 inhalations taken 15 to 30 minutes prior to the activity. Product labeling specifies that inhaled doses should generally not be repeated more often than every 4 hours. For the nebulizer solution, the usual starting dose is 2.5 mg administered over 5 to 15 minutes, which may be repeated up to four times daily.

Contextual Use Requirements

Correct administration involves specific procedural steps. The pMDI device must be primed with a few test sprays if it is new or has not been used for two weeks. Furthermore, the cleaning of the actuator, usually performed weekly with warm water, is a requirement for maintaining correct dose delivery. Dosing rules for pediatric patients (ge 4 years) often align with adult dosing for acute use, though the safety and efficacy are not established for very young children (typically <4 years) in the inhaled form.

Research Evidence / Overview of Studies for Butovent

Evidence for Acute Bronchial Asthma

Butovent (Salbutamol) was studied in research contexts involving fluctuating or unstable symptoms of asthma, particularly when symptoms become more noticeable. Research in this area primarily consists of numerous Short-term Randomized Controlled Trials (RCTs), as well as Systematic Reviews and Meta-analyses. This extensive research explored outcomes related to physical discomfort and functional imbalance by measuring changes in lung function, such as Forced Expiratory Volume in 1 second (FEV1), immediately following administration.

Studies focused on research exploring short-term symptom changes, with most of the follow-up lasting only minutes or a few hours. Findings describe patterns observed where changes in functional airway measures were tracked over defined time intervals. The research base in this area is categorized by regulatory bodies as having a High evidence level regarding research exploration of its use in acute symptom settings. Data are still emerging from large-scale observational studies that have tracked frequent or high-quantity use of rescue inhalers (SABAs), noting that increased frequency was associated with a higher reported risk of subsequent severe exacerbations.

Evidence for Chronic Obstructive Pulmonary Disease (COPD)

Research explored the use of Butovent in conditions associated with acute or disruptive episodes of Chronic Obstructive Pulmonary Disease (COPD). The evidence base includes Randomized Controlled Trials (RCTs) and Historical Cohort Studies that examined long-term usage patterns. Studies monitored various outcomes reflecting daily functioning, including changes in lung function (FEV1) and patient-reported outcomes describing perceived discomfort. The evidence level for this indication is broadly designated as Moderate.

Analyses of patient cohorts described a correlation pattern where the reported frequency of medication use was observed in some studies to be related to a higher rate of future COPD exacerbations. Long-term effects are not fully established regarding the drug's impact on the progression of COPD over many years. Research is ongoing to clarify the precise relationship between increased daily SABA use and the risk of future exacerbations, as well as to clarify usage patterns.

Key Evidence Gaps and Areas of Uncertainty

Research provides context but not individual predictions. The main research limitation frames include the fact that the primary evidence base focuses on short-term efficacy, meaning that long-term effects are not fully established. Furthermore, the evidence quality varies across studies when examining specific subgroups, and subgroup findings are uncertain in some cases. Research is ongoing to fully understand the clinical implications of frequent use of Butovent.

Key Studies & References

1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 GOLD Report)
2. Albuterol Inhalation Solution Prescribing Information (US FDA Label)
3. Adverse Outcomes Associated With Short-Acting Beta-Agonist Overuse in Asthma: A Systematic Review and Meta-Analysis
4. Short-acting beta 2 agonists (SABA): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines (UK MHRA/GOV.UK)

Common questions about Butovent (FAQ)

Q: How long does the effect of a Butovent dose usually last?

According to official product information, the bronchodilating effect of a dose of Butovent typically lasts for 4 to 6 hours. This short duration of action is consistent with its classification as a quick-relief or reliever medicine.

Q: What happens if a dose of Butovent is missed?

Butovent is generally used as-needed to treat or prevent acute symptoms. If the medicine is prescribed for a regular schedule, regulatory guidance suggests taking the missed dose as soon as possible. However, if it is almost time for your next scheduled dose, it is generally recommended to take only the scheduled dose and avoid taking extra doses.

Q: Is it necessary to avoid caffeine while taking Butovent?

Official drug information cautions that Butovent, like caffeine, can affect the heart rate and blood pressure because they both stimulate the sympathetic nervous system. Using them together may potentially amplify these effects. It is important for individuals, particularly those with existing heart conditions, to discuss any concerns about combining these with a healthcare provider.

Q: Is Butovent generally appropriate for older adults?

Official warnings note that the medicine should be used with awareness of pre-existing conditions due to its sympathomimetic effects. These include cardiovascular disorders (such as high blood pressure) and diabetes, which may be more common in older adults. The suitability of this medication for an individual, regardless of age, requires evaluation by a healthcare provider.

Q: Is Butovent available without a prescription in any countries?

The active ingredient in Butovent (salbutamol/albuterol) is generally classified as a prescription-only drug in major regulatory jurisdictions. This requirement ensures that its use is overseen by a healthcare professional due to its specific classification and potential side effects.

Q: Is Butovent known to cause difficulty sleeping or insomnia?

Yes, official patient information documents indicate that trouble sleeping, including insomnia, has been reported as a potential side effect. This is thought to be related to the drug's stimulating effect on the body.

Q: Are there any known interactions between Butovent and common supplements like Vitamin D or magnesium?

Official drug labels focus on interactions with specific prescription drug classes and do not typically list common vitamins or minerals like Vitamin D or magnesium. However, official guidance emphasizes the importance of a patient's complete disclosure of all supplements, vitamins, and herbs to their healthcare provider.

Q: Does the time of day a person takes Butovent make a difference?

Butovent is primarily prescribed for as-needed use to manage or prevent symptoms. Therefore, the time of day generally does not impact its effectiveness for acute relief. Strict adherence to the prescribed frequency is important to avoid overuse of the medicine.

Q: Why does the official literature mention certain foods or drinks should be limited with Butovent?

The official literature warns against combining the medicine with other agents that stimulate the sympathetic nervous system (sympathomimetics). This warning extends to certain products, such as those with high amounts of caffeine, because they can amplify the cardiovascular side effects of Butovent.

Q: What are the signs that Butovent might be irritating my throat or mouth?

Sore throat and general throat irritation are listed as common side effects in official patient information. These symptoms may occur as a result of the local application of the inhaled medicine.

Q: Why is Butovent described as a maintenance treatment by some sources?

Regulatory documents classify Butovent as a Short-Acting beta2-Agonist (SABA), meaning its official purpose is for acute, as-needed relief, not daily maintenance control. If the medicine needs to be used more often than prescribed, official guidelines state that this signals a worsening respiratory condition that requires re-evaluation.

Q: Does Butovent interact with common painkillers like ibuprofen or acetaminophen?

Official drug labels generally do not list a direct drug-to-drug interaction with common painkillers like ibuprofen or acetaminophen. However, regulatory warnings note that non-steroidal anti-inflammatory drugs (NSAIDs) can sometimes cause respiratory reactions in individuals with asthma. Discussing the use of painkillers is important to evaluate any potential individual risks.

Q: Is Butovent known to cause dry mouth or changes in taste?

Yes, dry mouth and changes in taste have been reported as potential side effects. These reactions are typically noted in the official patient information for the medicine.

Q: Do official documents mention any potential for dependence on Butovent?

Official literature does not list physical addiction or dependence as a primary concern. However, official guidance stresses that increasing the dose or frequency of use should not be done without consultation, as increased use is recognized as a signal indicating a potential problem with disease control.

Q: How does Butovent affect exercise capacity in people with the condition it treats?

Butovent is specifically indicated to be used before physical activity to prevent the sudden symptoms of bronchospasm that can be triggered by exercise. By preventing these symptoms, the medicine is intended to help maintain normal exercise capacity.

Q: Can Butovent affect the results of any common medical tests?

Yes, official guidelines indicate that the medicine can affect certain medical tests. For instance, it is typically required to be withheld for a period of time before pulmonary function tests (PFTs) or cardiac stress tests to prevent interference with the baseline measurements.

Q: Is there any research evidence on Butovent's use in pregnant animals (pre-clinical data)?

Official risk summaries mention that animal reproduction studies have been conducted. These studies showed evidence of anomalies, such as cleft palate, in offspring at doses less than or equal to the maximum recommended human daily dose.

Q: Does Butovent interact with alcohol, based on regulatory information?

Official labels typically do not list a direct, specific interaction with alcohol. However, since the medicine and alcohol can both potentially affect the cardiovascular system, the potential interaction and overall safety should be evaluated by a healthcare professional.

Q: Are there specific instructions for what to do if a person develops a rash after using Butovent?

A rash or hives can be a sign of a serious, immediate hypersensitivity reaction to the medicine. Official warnings indicate that if a rash or hives occurs, the medicine's use should be discontinued immediately and emergency medical attention should be sought.

Q: Is Butovent the same kind of medicine as other treatments for this condition?

No, Butovent is classified as a Short-Acting beta2-Agonist (SABA) designed to provide immediate relief by relaxing the airways. This makes it chemically and functionally distinct from other common inhaled medicines used for the same condition, such as long-acting bronchodilators or corticosteroids.

Q: Are there common over-the-counter cold medicines that interact with Butovent?

Yes, official warnings note that Butovent can interact with other adrenergic drugs, or sympathomimetics. This group includes certain active ingredients found in common over-the-counter cold and sinus medicines, which may increase the risk of cardiovascular side effects.

Q: What kind of warnings are included on the official label for Butovent?

Key warnings listed in official prescribing information include the potential for Paradoxical Bronchospasm, which is a sudden worsening of breathing after inhalation. Other warnings cover the risks of serious Cardiovascular Effects (like rapid heart rate) and Hypersensitivity Reactions.

Q: Are there research papers looking at the effects of Butovent in different ethnic groups?

Regulatory reviews often indicate that clinical trial data may be limited or have some uncertainty when examining findings across specific subgroups, which includes diverse ethnic populations. The evidence quality for these specific subgroup findings is often noted as having some uncertainty.

Q: Can Butovent be used with other inhaled treatments?

Yes, it can be used alongside many other inhaled treatments. However, caution is advised and specific combinations have procedural constraints. For example, when used with certain other inhaled medicines, special precautions must be taken to prevent the mist from contacting the eyes.

Q: If a person feels fine, should they still continue using Butovent as prescribed?

Official documents state that the medicine is specifically intended for as-needed acute relief of symptoms or for preventing symptoms before exercise. It is not generally intended for daily use if the person is otherwise asymptomatic.

Q: Are there any specific activities or conditions that should be avoided while using Butovent?

Official warnings state that activities requiring mental alertness or physical control should be approached with awareness of potential side effects such as tremor, dizziness, or palpitations. This includes tasks such as driving or operating heavy machinery.

Q: What is the meaning of the different safety class ratings Butovent has?

Government agencies use classifications to categorize drug risks, such as those related to pregnancy or side effect frequency. Older systems (like A, B, C, D, X for pregnancy) are being updated in favor of detailed risk summaries and discussions that provide comprehensive context.

Q: Are there warnings about using Butovent with other stimulants?

Yes, official warnings exist against the concurrent use of Butovent with other adrenergic drugs (stimulants). This is because the combination may enhance the side effects observed on the cardiovascular system.

Q: Does the efficacy of Butovent depend on the type of device used to deliver it?

Official labeling emphasizes that the correct administration procedure for the specific device is necessary to ensure the intended dose is delivered. Proper technique and maintenance are essential for maximizing the expected effectiveness of the medicine.

Q: What is the difference between Butovent and similar inhalers mentioned online?

Butovent is classified as a Short-Acting beta2-Agonist (SABA). This means it is designed for rapid, short-term relief, making it fundamentally different from other inhaler types that are used for long-term control of inflammation or maintenance of the airways.

Butovent (albuterol/salbutamol) must be stored and handled according to official regulatory specifications to maintain product integrity and safety.

Storage Requirements

Disposal Instructions

The inhaler must be discarded when the dose indicator displays 0 or after the product's expiration date, whichever comes first. The pressurized canister must never be thrown into a fire or an incinerator. Unused or expired Butovent should be safely discarded using an authorized drug take-back program or following other government-approved household disposal procedures.